Should I buy or sell Regulus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks .

What is Regulus Therapeutics' stock price target for 2024?

5 brokers have issued 12-month target prices for Regulus Therapeutics' shares. Their RGLS share price targets range from $3.00 to $11.00. On average, they expect the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 181.0% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts .

How have RGLS shares performed in 2024?

Regulus Therapeutics' stock was trading at $1.28 at the beginning of 2024. Since then, RGLS shares have increased by 101.6% and is now trading at $2.58. View the best growth stocks for 2024 here .

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RGLS earnings forecast .

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) issued its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40).

When did Regulus Therapeutics' stock split?

Shares of Regulus Therapeutics reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com . Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO) , Flexion Therapeutics (FLXN) , Cytori Therapeutics (CYTX) , PTC Therapeutics (PTCT) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Gilead Sciences (GILD) , Synergy Pharmaceuticals (SGYP) and Trevena (TRVN) .

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free RGLS Stock Alerts

$2.58

-0.20 (-7.19%)

(As of 02:10 PM ET)

Compare

Today's Range: $2.56
▼
$2.78
50-Day Range: $1.30
▼
$2.88
52-Week Range: $1.08
▼
$3.79

Volume: 383,842 shs
Average Volume: 2.64 million shs
Market Capitalization: $168.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.25

Get Regulus Therapeutics alerts:

Regulus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 181.0% Upside
$7.25 Price Target
Short Interest: Bearish
9.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.87
Based on 4 Articles This Week
Insider Trading: Selling Shares
$23,857 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.52) to ($0.75) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

349th out of 930 stocks

Pharmaceutical Preparations Industry

159th out of 426 stocks

4.4

Analyst's Opinion

Consensus Rating
Regulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Regulus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
9.44% of the float of Regulus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Regulus Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regulus Therapeutics has recently increased by 5.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Regulus Therapeutics does not currently pay a dividend.
Dividend Growth
Regulus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RGLS.

3.8

News and Social Media Coverage

News Sentiment
Regulus Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.
Search Interest
18 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
11 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regulus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,857.00 in company stock.
Percentage Held by Insiders
Only 8.41% of the stock of Regulus Therapeutics is held by insiders.
Percentage Held by Institutions
92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.52) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regulus Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regulus Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Regulus Therapeutics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

RGLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGLS Stock News Headlines

April 16, 2024 | americanbankingnews.com

Regulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com

April 12, 2024 | americanbankingnews.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of "Moderate Buy" by Brokerages

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 10, 2024 | seekingalpha.com

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

March 28, 2024 | markets.businessinsider.com

Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs

March 26, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones

March 23, 2024 | finance.yahoo.com

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

March 22, 2024 | finanznachrichten.de

Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 21, 2024 | investorplace.com

RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023

March 21, 2024 | finance.yahoo.com

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

March 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Data

March 15, 2024 | finance.yahoo.com

RGLS Mar 2024 7.500 put

March 14, 2024 | finance.yahoo.com

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

March 13, 2024 | markets.businessinsider.com

Regulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Position

March 12, 2024 | marketwatch.com

Regulus Therapeutics Shares Soar on Funding, Study Data

March 12, 2024 | markets.businessinsider.com

Regulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mln

March 12, 2024 | msn.com

Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?

March 12, 2024 | markets.businessinsider.com

Regulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429

March 12, 2024 | msn.com

Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell

March 12, 2024 | prnewswire.com

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

March 12, 2024 | prnewswire.com

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

February 16, 2024 | money.usnews.com

Regulus Therapeutics Inc

January 3, 2024 | msn.com

Regulus concludes enrolment in Phase I trial’s third cohort for ADPKD

January 2, 2024 | finance.yahoo.com

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

December 27, 2023 | seekingalpha.com

Regulus Therapeutics files for $150M mixed shelf

December 23, 2023 | morningstar.com

Regulus Therapeutics Inc RGLS

See More Headlines

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:RGLS
CUSIP: 75915K10
CIK: 1505512
Web: www.regulusrx.com
Phone: (858) 202-6300
Fax: N/A
Employees: 30
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.25
High Stock Price Target: $11.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +176.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -109.21%
Return on Assets: -80.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.05 per share
Price / Book: 2.50

Miscellaneous

Outstanding Shares: 65,460,000
Free Float: 59,959,000
Market Cap: $171.51 million
Optionable: Optionable
Beta: 1.56

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Joseph P. Hagan M.B.A. (Age 55)
CEO & Director
Comp: $920.73k
Ms. Crispina Calsada CPA (Age 54)
Chief Financial Officer
Comp: $500.87k
Mr. Christopher Ray Aker J.D. (Age 63)
Senior VP, General Counsel & Corporate Secretary
Comp: $524.79k
Dr. Preston S. Klassen M.D. (Age 55)
M.H.S., President, Head of Research & Development and Director
Mr. Daniel J. Penksa (Age 38)
VP of Finance & Controller
Dr. Claire Susan Padgett M.S.
M.T., Ph.D., Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D.
M.S., Senior Vice President of Clinical Development & Regulatory
Mr. Edmund Lee Ph.D.
Vice President of Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RGLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGLS shares.
View RGLS analyst ratings or view top-rated stocks.
What is Regulus Therapeutics' stock price target for 2024?: 5 brokers have issued 12-month target prices for Regulus Therapeutics' shares. Their RGLS share price targets range from $3.00 to $11.00. On average, they expect the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 181.0% from the stock's current price.
View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts.
How have RGLS shares performed in 2024?: Regulus Therapeutics' stock was trading at $1.28 at the beginning of 2024. Since then, RGLS shares have increased by 101.6% and is now trading at $2.58.
View the best growth stocks for 2024 here.
When is Regulus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RGLS earnings forecast.
How were Regulus Therapeutics' earnings last quarter?: Regulus Therapeutics Inc. (NASDAQ:RGLS) issued its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40).

When did Regulus Therapeutics' stock split?: Shares of Regulus Therapeutics reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?: 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Regulus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).
How do I buy shares of Regulus Therapeutics?: Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RGLS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Regulus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Regulus Therapeutics Stock (NASDAQ:RGLS)

RGLS Stock Price History

RGLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RGLS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™